BioTools and Schrödinger collaborate to develop small molecule drugs

By The Science Advisory Board staff writers

January 10, 2022 -- BioTools is collaborating with Schrödinger to improve the process of identifying three-dimensional chiral stereo structures using Schrödinger's physics-based software platform. Combining BioTools' experimental results with calculations derived from Schrödinger's quantum chemistry engine Jaguar can allow chemists to determine the absolute configuration rapidly.

BioTools has developed a vibrational circular dichroism (VCD) technology and provides proprietary instrumentation and analytical services for structure elucidation of chiral molecules.

A molecule with a chiral center exists in one of two mirror-image forms, which can exhibit different biological properties. Identification of the molecule's stereo configuration, or handedness, is known as the determination of absolute configuration. It can be achieved via VCD technology, which includes both experimental measurements and theoretically predicted results, the firm said.

For over 21 years, the VCD method has been an alternative or replacement to traditional x-ray crystallography. VCD technology does not require a single crystal, and it requires a very low quantity of material that can be easily recovered. VCD has been published as a standard method in the U.S. Pharmacopeia, and approximately 10,000 absolute configurations have now been determined with VCD.

Financial details of the collaboration were not disclosed


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.